A biotech newsletter’s week: Moderna, 340B, insulin

STAT’s Readout previews an FDA decision on Moderna’s mRNA flu shot, a revived 340B rebate fight and scrutiny of Lilly’s insulin pricing.

STAT's Readout newsletter for 3 August 2026 previews an upcoming FDA decision on Moderna's mRNA influenza vaccine, a revived fight over 340B rebates, and fresh legal scrutiny of Eli Lilly's insulin pricing. The headline question — whether a pharmaceutical mega-merger is in the making — is posed rather than answered in the portion that is public.

Two of the three checkable items bear directly on what medicine costs. The 340B programme governs discounted drug pricing for safety-net providers, and insulin pricing has been the most visible test of whether a drug can get cheaper without waiting for a patent to expire. Both are distribution fights rather than discovery ones, which is where a great deal of the actual price of health care is settled.

The article is behind STAT's paywall beyond its opening. Only the items above could be checked; the merger claim in the headline could not.

Source: STAT